Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of oral belumosudil for chronic lung allograft dysfunction after bilateral lung transplantation
MOH_2023-08-20_012889Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic lung allograft dysfunction (CLAD) comparing Belumosudil with Placebo (2 arms). Started Aug 2023; status: recruiting.
02
Drugs
belumosudil
03
Conditions
chronic lung allograft dysfunction (CLAD)
Beyond the preview
Go deeper on MOH_2023-08-20_012889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-20_012889.